MaxCyte, Inc.

MXCT · Nasdaq · ·

Vergleichen

1,20 $+1,7 %Schluss 13. Nov.

Zahlen bis 30. September 2026, aus dem 10-Q vom 10. November 2026

1W: -4,8 %
1M: -4,0 %

Just reported

Q3 2026 results

From MaxCyte's results release of 10. November 2026; its quarterly report has since been filed.

Revenue
Actual
10,2M $
+49 % y/y
+40 % q/q
Guided
—
No guide given
EPS, GAAP
Actual
-0,05 $
Guided
—
No guide given
Operating income, GAAP
Actual
-6M $
Guided
—
No guide given

Company outlook

Full year 2026

Revenue34,5M $+4,5 % y/y Raised +1,5 %

Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.

Keep exploring

The themes MaxCyte is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.

Highest-graded in Medical Devices

Graded A or B and worth $2B or more: A first, then the largest.

All 133 graded companies in its industry

Grade rose recently in Healthcare

Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.

All grade rises

Vollständige Abschlüsse →

Gebaut aus den eigenen Einreichungen von MaxCyte, Inc. bei der US-Börsenaufsicht Securities and Exchange Commission (SEC). Die Zahlen sind wie berichtet, die Historie je Aktie auf die heutige Aktienbasis umgerechnet. Dies beschreibt ein Unternehmen — es ist keine Anlageberatung und keine Kauf- oder Verkaufsempfehlung.

MaxCyte, Inc.

MaxCyte, Inc.

Q3 2026 results

Revenue

EPS, GAAP